McClellan to lead empowered FDA
This article was originally published in The Gray Sheet
Executive Summary
Passage of the medical device user fee act, the bioterrorism bill and the reauthorization of prescription drug user fees in the 107th Congress "represent the most substantial expansion of the agency in more than a generation," the incoming FDA commissioner says Nov. 6 at the Schwab Washington Research Group annual symposium in Washington, D.C. "We'll have the opportunity and resources to achieve new levels of improvement in getting safe and effective treatments to market," McClellan said on assuming his new responsibilities Nov. 8...